Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03403205 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
A Phase 3 study, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 214
- Enrollment target
NCT03403205 is a Phase 3 study that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 214 participants.
The verdict
NCT03403205, a Phase 3 study, was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 214 participants
- Enrollment target
Study Summary
The study will evaluate the efficacy and safety of ALXN1840 (formerly called WTX101) administered for 48 weeks compared to standard of care (SoC) in Wilson Disease (WD) participants aged 12 and older in the Primary Evaluation Period. In addition, efficacy and safety will be evaluated during an optional 60-month Extension Period.
Interventions
- DRUG ALXN1840
- DRUG SoC Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2018-02-22 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03403205
The ClinicalTrials.gov registry entry for NCT03403205 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ALXN1840 is the first listed.
NCT03403205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03403205 about?
NCT03403205 is a clinical study titled "Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease". The study will evaluate the efficacy and safety of ALXN1840 (formerly called WTX101) administered for 48 weeks compared to standard of care (SoC) in Wilson Disease (WD) participants aged 12 and older in the Primary Evaluation Period. In addition, efficacy and safety will be evaluated during an optio...
What is the current status of trial NCT03403205?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 214 participants. The study started on 2018-02-22. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT03403205?
The interventions under investigation include: ALXN1840 (DRUG), SoC Therapy (DRUG).
Who is sponsoring clinical trial NCT03403205?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.